|
US7112324B1
(en)
*
|
1998-04-21 |
2006-09-26 |
Micromet Ag |
CD 19×CD3 specific polypeptides and uses thereof
|
|
JP3425536B2
(ja)
|
1999-04-21 |
2003-07-14 |
株式会社チップトン |
コーティング装置
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
MXPA06004035A
(es)
|
2003-10-16 |
2006-08-31 |
Micromet Ag |
Aglutinantes cd3 de-inmunizados multi-especificos.
|
|
EP1716178B1
(en)
|
2004-02-16 |
2010-08-11 |
Micromet AG |
Less immunogenic binding molecules
|
|
BRPI0513826A2
(pt)
|
2004-07-26 |
2010-06-22 |
Dow Global Technologies Inc |
processo para expressão de proteìna melhorada através de engenharia de cepa
|
|
PL1874821T3
(pl)
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
|
CN103145842A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
AU2013202375B2
(en)
*
|
2005-12-16 |
2016-10-27 |
Amgen Research (Munich) Gmbh |
Means and Methods for the Treatment of Tumorous Diseases
|
|
HRP20150175T1
(en)
*
|
2005-12-16 |
2015-03-27 |
Amgen Research (Munich) Gmbh |
Means and methods for the treatment of tumorous diseases
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
JP2010502224A
(ja)
|
2006-09-08 |
2010-01-28 |
アボット・ラボラトリーズ |
インターロイキン１３結合タンパク質
|
|
RU2495882C2
(ru)
*
|
2006-09-08 |
2013-10-20 |
Медиммун, Ллк. |
Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US9394571B2
(en)
|
2007-04-27 |
2016-07-19 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
EP2014680A1
(en)
*
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
|
DK2211904T3
(en)
*
|
2007-10-19 |
2016-10-24 |
Seattle Genetics Inc |
Cd19-binding agents and uses thereof
|
|
WO2009070642A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
|
SG190572A1
(en)
*
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201006485A
(en)
*
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CN102149825B
(zh)
*
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
|
PE20110385A1
(es)
|
2008-07-18 |
2011-06-22 |
Bristol Myers Squibb Co |
Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
|
|
EP2352765B1
(en)
*
|
2008-10-01 |
2018-01-03 |
Amgen Research (Munich) GmbH |
Cross-species-specific single domain bispecific single chain antibody
|
|
EP2370467B1
(en)
|
2008-10-01 |
2016-09-07 |
Amgen Research (Munich) GmbH |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
US20110293619A1
(en)
*
|
2008-10-01 |
2011-12-01 |
Micromet Ag |
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
|
|
DK2352763T4
(da)
|
2008-10-01 |
2022-10-17 |
Amgen Res Munich Gmbh |
Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
|
|
KR101695327B1
(ko)
|
2008-11-07 |
2017-01-11 |
암젠 리서치 (뮌헨) 게엠베하 |
급성 림프구성 백혈병의 치료방법
|
|
PL2918604T3
(pl)
|
2008-11-07 |
2018-05-30 |
Amgen Research (Munich) Gmbh |
Leczenie pediatrycznej ostrej białaczki limfoblastycznej
|
|
UY32808A
(es)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
WO2011028811A2
(en)
*
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
BR112012008833A2
(pt)
*
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
|
RS54655B2
(sr)
*
|
2009-10-27 |
2021-04-29 |
Amgen Res Munich Gmbh |
Dozni režim za primenu cd19xcd3 bispecifičnog antitela
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
CA2785907A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CN102250245B
(zh)
*
|
2010-05-27 |
2014-05-14 |
四川大学 |
抗b细胞淋巴瘤的双特异性抗体及其用途
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
AU2011311673B2
(en)
|
2010-10-05 |
2015-09-17 |
F. Hoffmann-La Roche Ag |
Antibodies against human TWEAK and uses thereof
|
|
CN103459425B
(zh)
|
2010-10-27 |
2015-11-25 |
安进研发（慕尼黑）股份有限公司 |
用于治疗dlbcl的组合物
|
|
ES2758994T3
(es)
|
2010-11-05 |
2020-05-07 |
Zymeworks Inc |
Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
|
EA026075B1
(ru)
|
2010-11-10 |
2017-02-28 |
Эмджен Рисерч (Мьюник) Гмбх |
Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами
|
|
EP3974453A3
(en)
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
EP2683735A1
(en)
|
2011-03-10 |
2014-01-15 |
HCO Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
|
KR102345943B1
(ko)
|
2011-04-28 |
2021-12-31 |
암젠 리서치 (뮌헨) 게엠베하 |
잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법
|
|
KR102060389B1
(ko)
*
|
2011-05-21 |
2019-12-31 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
|
WO2013048243A1
(en)
*
|
2011-09-29 |
2013-04-04 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
EP2797600A4
(en)
|
2011-12-28 |
2015-09-16 |
Pozen Inc |
IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
|
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
|
|
CA2860914A1
(en)
|
2012-01-13 |
2013-07-18 |
Apo-T B.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
JP6509724B2
(ja)
|
2012-04-20 |
2019-05-08 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Ｃｄ３結合ポリペプチド
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
JP2015524255A
(ja)
|
2012-07-13 |
2015-08-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
|
|
TW202037609A
(zh)
|
2012-11-01 |
2020-10-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
|
JP6499079B2
(ja)
*
|
2012-11-13 |
2019-04-10 |
バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ |
クローディンを発現するガン疾患を処置するための剤
|
|
US9562110B2
(en)
*
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US9486475B2
(en)
|
2013-02-08 |
2016-11-08 |
Amgen Research (Munich) Gmbh |
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
|
CN105813654B
(zh)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
Tem8抗体及其用途
|
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
|
JP2017507900A
(ja)
|
2013-12-17 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
|
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
RU2016132863A
(ru)
*
|
2014-01-15 |
2018-02-20 |
Займворкс Инк. |
БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ
|
|
DK3105252T3
(da)
|
2014-02-12 |
2019-10-14 |
Michael Uhlin |
Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
|
|
EP3699195A3
(en)
|
2014-03-28 |
2020-11-04 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
CN105017422A
(zh)
*
|
2014-04-30 |
2015-11-04 |
山东百因制药技术有限公司 |
一种抗cd3/抗cd19双特异性抗体及其应用
|
|
SI3149480T1
(sl)
|
2014-05-30 |
2019-05-31 |
Amgen Research (Munich) Gmbh |
Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
|
|
WO2016001810A1
(en)
|
2014-07-01 |
2016-01-07 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
SG10201913782UA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
|
US9611325B2
(en)
|
2014-07-21 |
2017-04-04 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody HER2xCD3
|
|
WO2016036678A1
(en)
*
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
WO2016073791A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
US10066002B2
(en)
|
2014-11-05 |
2018-09-04 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
WO2016077789A1
(en)
|
2014-11-14 |
2016-05-19 |
The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
|
ES2744540T3
(es)
*
|
2014-12-05 |
2020-02-25 |
Hoffmann La Roche |
Anticuerpos anti-CD79b y procedimientos de uso
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
PL3560953T3
(pl)
|
2014-12-24 |
2024-05-13 |
Autolus Limited |
Komórka
|
|
CN104592393B
(zh)
*
|
2015-01-21 |
2018-09-28 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体cd19×cd3的构建及应用
|
|
CN107635578A
(zh)
|
2015-02-05 |
2018-01-26 |
Stc.Unm 公司 |
抗前‑bcr拮抗剂和方法
|
|
EP3262217A4
(en)
|
2015-02-24 |
2018-07-18 |
BioAtla LLC |
Conditionally active biological proteins
|
|
WO2016138160A1
(en)
|
2015-02-24 |
2016-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
EP3265567B1
(en)
|
2015-03-02 |
2020-07-29 |
Conagen Inc. |
Regulatory elements from labyrinthulomycetes microorganisms
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
ES2789348T3
(es)
|
2015-03-20 |
2020-10-26 |
Us Health |
Anticuerpos neutralizantes para GP120 y sus usos
|
|
SG11201708804WA
(en)
|
2015-05-07 |
2017-11-29 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
US9708412B2
(en)
*
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
AR105618A1
(es)
|
2015-05-29 |
2017-10-25 |
Genentech Inc |
Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
KR102689256B1
(ko)
|
2015-06-17 |
2024-07-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
|
EP3322735A4
(en)
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
|
|
TWI796283B
(zh)
*
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI717375B
(zh)
*
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
WO2017079479A1
(en)
|
2015-11-03 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Neutralizing antibodies to hiv-1 gp41 and their use
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
TW201720458A
(zh)
*
|
2015-12-04 |
2017-06-16 |
宏觀基因股份有限公司 |
能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
|
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
JOP20170017B1
(ar)
*
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CN109071667A
(zh)
*
|
2016-03-08 |
2018-12-21 |
马弗里克治疗公司 |
可诱导性结合蛋白和使用方法
|
|
AU2017235543B2
(en)
*
|
2016-03-16 |
2020-05-14 |
Conagen, Inc. |
Production of proteins in labyrinthulomycetes
|
|
SG11201809316XA
(en)
*
|
2016-04-28 |
2018-11-29 |
Biomunex Pharmaceuticals |
Bispecific antibodies targeting egfr and her2
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
US11339225B2
(en)
|
2016-05-12 |
2022-05-24 |
Asclepius (Suzhou) Technology Company Group, Co., Ltd. |
Bispecific antigen-binding construct and preparation method and use thereof
|
|
CN107365387B
(zh)
|
2016-05-12 |
2022-03-15 |
阿思科力(苏州)生物科技有限公司 |
一种双特异性抗原结合构建体及其制备方法和应用
|
|
WO2018220099A1
(en)
|
2017-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
JP7010854B2
(ja)
|
2016-06-14 |
2022-01-26 |
ゼンコア インコーポレイテッド |
二重特異性チェックポイント阻害剤抗体
|
|
KR20250175345A
(ko)
|
2016-06-21 |
2025-12-16 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
CN109715663B
(zh)
|
2016-06-28 |
2022-11-25 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
AU2017291262A1
(en)
*
|
2016-06-30 |
2019-01-03 |
F. Hoffmann-La Roche Ag |
Improved adoptive T-cell therapy
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
PE20241349A1
(es)
|
2016-09-14 |
2024-07-03 |
Teneobio Inc |
Anticuerpos de union a cd3
|
|
MY203000A
(en)
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
US10633454B2
(en)
|
2016-11-01 |
2020-04-28 |
Conagen Inc. |
Expression of modified glycoproteins and glycopeptides
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
JP2019535262A
(ja)
*
|
2016-11-11 |
2019-12-12 |
オートラス リミテッド |
キメラ抗原受容体
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
AU2017380981B2
(en)
|
2016-12-19 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1BB (CD137) agonists
|
|
KR102692708B1
(ko)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
IL317134A
(en)
|
2016-12-21 |
2025-01-01 |
Teneobio Inc |
An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
|
|
CN106589129B
(zh)
*
|
2016-12-30 |
2021-03-05 |
上海近岸生物科技有限公司 |
一种结合cd19、cd3和cd28的三功能分子及其应用
|
|
WO2018120842A1
(zh)
*
|
2016-12-30 |
2018-07-05 |
上海欣百诺生物科技有限公司 |
一种双功能分子及其应用
|
|
WO2018120843A1
(zh)
*
|
2016-12-30 |
2018-07-05 |
上海近岸生物科技有限公司 |
一种三功能分子及其应用
|
|
CN108264559B
(zh)
*
|
2016-12-30 |
2021-08-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞正共刺激分子的三功能分子及其应用
|
|
CN108264561B
(zh)
*
|
2016-12-30 |
2021-09-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
|
|
AU2018219887B2
(en)
|
2017-02-08 |
2024-08-15 |
Dragonfly Therapeutics, LLC |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
CN110944661A
(zh)
|
2017-02-20 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
结合her2、nkg2d和cd16的蛋白质
|
|
KR20240125061A
(ko)
*
|
2017-03-27 |
2024-08-19 |
바이오뮤넥스 파마슈티컬스 |
안정적인 다중특이적 항체
|
|
MX2019011769A
(es)
|
2017-04-03 |
2019-11-07 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1.
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
CN110945026B
(zh)
|
2017-06-20 |
2024-03-19 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
AR112257A1
(es)
|
2017-06-21 |
2019-10-09 |
Gilead Sciences Inc |
Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
EA202090020A1
(ru)
|
2017-07-10 |
2020-04-28 |
Интернэшнл - Драг - Дивелопмент - Байотек |
Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
|
|
US11525004B2
(en)
|
2017-07-20 |
2022-12-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Recombinant CD123-binding antibodies
|
|
KR102794369B1
(ko)
|
2017-08-01 |
2025-04-15 |
에이비 테라퓨틱스 인코퍼레이티드 |
이중특이 항체 및 그의 용도
|
|
EP4029877B1
(en)
|
2017-08-03 |
2024-01-17 |
Amgen Inc. |
Interleukin-21 muteins and methods of treatment
|
|
KR20200068647A
(ko)
|
2017-08-11 |
2020-06-15 |
시티 오브 호프 |
트랜스페린 수용체 (TfR)에 대한 RNA 앱타머
|
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
AU2018329920B2
(en)
|
2017-09-08 |
2022-12-01 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
MX2020003395A
(es)
|
2017-10-13 |
2020-08-03 |
Merck Sharp & Dohme |
Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
|
|
BR112020007630A2
(pt)
|
2017-11-01 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
|
|
JP7404252B2
(ja)
*
|
2017-11-08 |
2023-12-25 |
ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド |
生体分子のコンジュゲートおよびその使用
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
KR20200098590A
(ko)
|
2017-12-12 |
2020-08-20 |
마크로제닉스, 인크. |
이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
MX2020006119A
(es)
|
2017-12-21 |
2020-08-24 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1.
|
|
IL275462B2
(en)
|
2017-12-22 |
2026-01-01 |
Genentech Inc |
Targeted integration of nucleic acids
|
|
JP2021508479A
(ja)
|
2017-12-27 |
2021-03-11 |
テネオバイオ， インコーポレイテッド |
ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
|
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
TW201930344A
(zh)
|
2018-01-12 |
2019-08-01 |
美商安進公司 |
抗ｐｄ-１抗體及治療方法
|
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
EP3746470A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Stabilized immunoglobulin domains
|
|
CA3237846A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
BR112020015994A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP7337079B2
(ja)
|
2018-02-15 |
2023-09-01 |
マクロジェニクス，インコーポレーテッド |
変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
RU2020130795A
(ru)
|
2018-02-21 |
2022-03-21 |
Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз |
Нейтрализующие антитела к env вич-1 и их применение
|
|
EP3765489B1
(en)
|
2018-03-13 |
2024-10-16 |
F. Hoffmann-La Roche AG |
Therapeutic combination of 4-1bb agonists with anti-cd20 antibodies
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
TW202519260A
(zh)
|
2018-07-02 |
2025-05-16 |
美商安進公司 |
抗steap1抗原結合蛋白
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
KR102835308B1
(ko)
|
2018-08-08 |
2025-07-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
EP3850013A4
(en)
|
2018-09-10 |
2022-10-05 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
|
|
AR114732A1
(es)
|
2018-09-18 |
2020-10-07 |
Hoffmann La Roche |
Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
|
|
KR102739487B1
(ko)
|
2018-09-21 |
2024-12-10 |
제넨테크, 인크. |
3중-음성 유방암에 대한 진단 방법
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
EP3877407B1
(en)
|
2018-11-05 |
2026-03-11 |
F. Hoffmann-La Roche AG |
Methods of producing two chain proteins in prokaryotic host cells
|
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
CR20210330A
(es)
|
2018-12-21 |
2021-07-20 |
Hoffmann La Roche |
ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
|
|
UA128001C2
(uk)
|
2018-12-21 |
2024-03-06 |
Ф. Хоффманн-Ля Рош Аг |
Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
|
|
AU2019403279A1
(en)
|
2018-12-21 |
2021-07-01 |
Genentech, Inc. |
Targeted integration of nucleic acids
|
|
EP3902830A1
(en)
|
2018-12-30 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Anti-rabbit cd19 antibodies and methods of use
|
|
US11098093B2
(en)
*
|
2019-01-07 |
2021-08-24 |
Shattuck Labs, Inc. |
Heterodimeric proteins for modulating gamma delta T cells
|
|
KR102794884B1
(ko)
|
2019-01-23 |
2025-04-15 |
제넨테크, 인크. |
진핵 숙주 세포에서 다합체 단백질을 생산하는 방법
|
|
US12463463B2
(en)
|
2019-01-28 |
2025-11-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CN109776683B
(zh)
*
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
WO2020206330A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
WO2020221792A1
(en)
|
2019-04-30 |
2020-11-05 |
Amgen Research (Munich) Gmbh |
Means and methods of treating burkitt lymphoma or leukemia
|
|
EP3962523A2
(en)
|
2019-05-03 |
2022-03-09 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
WO2020232247A1
(en)
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
WO2020236974A1
(en)
|
2019-05-21 |
2020-11-26 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
WO2021003297A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
|
CA3248329A1
(en)
|
2019-07-31 |
2025-11-29 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
CN110577603B
(zh)
*
|
2019-08-15 |
2021-12-28 |
北京东方百泰生物科技股份有限公司 |
一种抗cd3和抗cd19双特异性抗体
|
|
US20220289843A1
(en)
*
|
2019-08-19 |
2022-09-15 |
Elpis Biopharmaceuticals |
Anti-cd19 antibodies and uses thereof
|
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
PH12022550646A1
(en)
|
2019-09-18 |
2023-04-03 |
Genentech Inc |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
KR20220100963A
(ko)
|
2019-12-18 |
2022-07-18 |
에프. 호프만-라 로슈 아게 |
Hla-a2/mage-a4에 결합하는 항체
|
|
KR20220118527A
(ko)
|
2019-12-23 |
2022-08-25 |
제넨테크, 인크. |
아포지질단백질 l1-특이적 항체 및 이용 방법
|
|
WO2021146328A1
(en)
|
2020-01-13 |
2021-07-22 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
|
BR112022013730A2
(pt)
|
2020-01-13 |
2022-10-11 |
Aptevo Res & Development Llc |
Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
|
|
EP3865513A1
(en)
*
|
2020-02-17 |
2021-08-18 |
Fundación Para La Investigación Biomédica Del Hospital 12 De Octubre |
Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof
|
|
BR112022017924A2
(pt)
|
2020-03-10 |
2022-12-20 |
Massachusetts Inst Technology |
Composições e métodos para imunoterapia de câncer npm1c-positivo
|
|
JP2023518841A
(ja)
|
2020-03-26 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質が減少した修飾哺乳動物細胞
|
|
US20230265204A1
(en)
|
2020-04-24 |
2023-08-24 |
Hoffmann-La Roche Inc. |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
JP7512394B2
(ja)
|
2020-05-06 |
2024-07-08 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
PE20240080A1
(es)
|
2020-06-08 |
2024-01-16 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso
|
|
IL298999A
(en)
|
2020-06-11 |
2023-02-01 |
Provention Bio Inc |
Methods and compositions for the prevention of type 1 diabetes
|
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
|
PE20230835A1
(es)
|
2020-06-19 |
2023-05-19 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
|
PH12022553489A1
(en)
|
2020-06-19 |
2024-04-22 |
Hoffmann La Roche |
Antibodies binding to cd3 and folr1
|
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
CA3184747A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
JP2023532665A
(ja)
|
2020-06-24 |
2023-07-31 |
ジェネンテック， インコーポレイテッド |
核酸の標的化組み込み
|
|
PH12023550112A1
(en)
|
2020-07-17 |
2024-06-24 |
Genentech Inc |
Anti-notch2 antibodies and methods of use
|
|
EP4185616A1
(en)
*
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
|
WO2022026358A1
(en)
*
|
2020-07-27 |
2022-02-03 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination
|
|
US20240059797A1
(en)
*
|
2020-07-29 |
2024-02-22 |
Gritstone Bio, Inc. |
Engineered multi-specific antibodies and related methods of use and manufacture
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
CN116322763A
(zh)
|
2020-08-27 |
2023-06-23 |
学校法人顺天堂 |
抗切断型突变calr-cd3双特异性抗体及医药组合物
|
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
JP2023550148A
(ja)
|
2020-11-20 |
2023-11-30 |
シンシア・イノベーション・インコーポレイテッド |
がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
MX2023007133A
(es)
|
2020-12-17 |
2023-06-27 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos.
|
|
AU2022214319A1
(en)
|
2021-01-28 |
2023-08-03 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating cytokine release syndrome
|
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
EP4288455A1
(en)
|
2021-02-03 |
2023-12-13 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
AU2022221297A1
(en)
|
2021-02-09 |
2023-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
|
WO2022173689A1
(en)
|
2021-02-09 |
2022-08-18 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
|
EP4294837A1
(en)
|
2021-02-16 |
2023-12-27 |
Children's Health Care d/b/a Children's Minnesota |
Methods for treating b-all by administering a pre-bcr complex antagonist
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
EP4326855A1
(en)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modified mammalian cells
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
TW202244059A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
|
EP4341291A1
(en)
|
2021-05-21 |
2024-03-27 |
Aptevo Research and Development LLC |
Dosing regimens for protein therapeutics
|
|
JP2024520444A
(ja)
|
2021-05-24 |
2024-05-24 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を治療するための方法
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
JP7826449B2
(ja)
|
2021-07-13 |
2026-03-09 |
ジェネンテック， インコーポレイテッド |
サイトカイン放出症候群を予測する多変量モデル
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
US20240360233A1
(en)
|
2021-08-27 |
2024-10-31 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
|
CA3232223A1
(en)
|
2021-09-17 |
2023-03-23 |
Ying Fu |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
|
EP4415829A1
(en)
|
2021-10-15 |
2024-08-21 |
Amgen Research (Munich) GmbH |
Subcutaneous administration of cd19-binding t cell engaging antibodies
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
|
KR20240142563A
(ko)
|
2022-02-10 |
2024-09-30 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
코로나바이러스를 광범위하게 표적으로 하는 인간 모노클로날 항체
|
|
TW202342097A
(zh)
|
2022-02-25 |
2023-11-01 |
學校法人順天堂 |
抗突變calr抗體與其他藥劑組合而成之醫藥
|
|
MX2024011468A
(es)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
|
|
EP4499228A1
(en)
|
2022-03-28 |
2025-02-05 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CN116925234B
(zh)
*
|
2022-04-02 |
2024-05-31 |
合肥星眸生物科技有限公司 |
一种编码抗vegf-a和ang-2双特异性抗体的aav载体
|
|
EP4507790A1
(en)
|
2022-04-11 |
2025-02-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
TW202417504A
(zh)
|
2022-07-22 |
2024-05-01 |
美商建南德克公司 |
抗ｓｔｅａｐ１抗原結合分子及其用途
|
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
WO2024081918A1
(en)
|
2022-10-14 |
2024-04-18 |
Talem Therapeutics Llc |
Anti-trkb/cd3 antibodies and uses thereof
|
|
EP4611903A1
(en)
*
|
2022-11-01 |
2025-09-10 |
TeneoTwo, Inc. |
Methods of treating non-hodgkin lymphoma
|
|
EP4612178A1
(en)
|
2022-11-03 |
2025-09-10 |
F. Hoffmann-La Roche AG |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
KR20250107893A
(ko)
|
2022-11-15 |
2025-07-14 |
제넨테크, 인크. |
숙주 세포로의 트랜스포존 매개 통합 및 핵산의 표적 통합의 조합
|
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
|
WO2024137381A1
(en)
|
2022-12-19 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
|
WO2024138151A1
(en)
|
2022-12-22 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
|
|
EP4649148A1
(en)
|
2023-01-12 |
2025-11-19 |
Genentech, Inc. |
Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
CN120857940A
(zh)
|
2023-02-17 |
2025-10-28 |
瑞泽恩制药公司 |
对cd3/taa双特异性抗体有反应的诱导型nk细胞
|
|
JP2026510318A
(ja)
|
2023-03-06 |
2026-04-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ＥＧＦＲｖＩＩＩ／抗ＣＤ３抗体と腫瘍標的化４－１ＢＢアゴニストの併用療法
|
|
JP2026509243A
(ja)
|
2023-03-10 |
2026-03-17 |
ジェネンテック， インコーポレイテッド |
プロテアーゼとの融合およびその使用
|
|
EP4680638A1
(en)
|
2023-03-13 |
2026-01-21 |
F. Hoffmann-La Roche AG |
Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4-1bb (cd137) agonist
|
|
CN120936626A
(zh)
|
2023-03-31 |
2025-11-11 |
基因泰克公司 |
抗αvβ8整合素抗体及使用方法
|
|
EP4709752A1
(en)
|
2023-05-08 |
2026-03-18 |
F. Hoffmann-La Roche AG |
Targeted interferon alpha fusion proteins and methods of use
|
|
WO2024243423A1
(en)
|
2023-05-24 |
2024-11-28 |
Mozart Therapeutics, Inc. |
Cd8-specific binding proteins and methods of using the same
|
|
WO2024243355A1
(en)
|
2023-05-24 |
2024-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
|
|
KR20260026086A
(ko)
|
2023-06-21 |
2026-02-25 |
에프. 호프만-라 로슈 아게 |
Fap 표적화 림포톡신 베타 수용체 작용제를 이용한 조합 요법
|
|
EP4731668A1
(en)
|
2023-06-22 |
2026-04-29 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
AU2024300009A1
(en)
|
2023-07-21 |
2026-01-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies that broadly target coronaviruses
|
|
AU2024300993A1
(en)
|
2023-07-26 |
2026-01-22 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
WO2025085705A1
(en)
|
2023-10-18 |
2025-04-24 |
Genentech, Inc. |
Retroviral-like particle-reduced chinese hamster ovary production cell lines
|
|
WO2025106427A1
(en)
|
2023-11-14 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
|
|
TW202535955A
(zh)
|
2023-11-27 |
2025-09-16 |
丹麥商珍美寶股份有限公司 |
用於ｐｔｋ７檢測之抗體及方法
|
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025137284A2
(en)
|
2023-12-21 |
2025-06-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
TW202540166A
(zh)
|
2024-03-01 |
2025-10-16 |
德商安美基研究（慕尼黑）公司 |
用於治療自體免疫性疾病／自體免疫性病症的ｃｄ１９選擇性ｔ細胞接合分子
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025214418A1
(en)
*
|
2024-04-09 |
2025-10-16 |
Abogen Life Sciences (Shanghai) Co., Ltd. |
Agents that bind to cd3 and cd19, nucleic acids encoding the same and uses thereof
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2025233264A1
(en)
|
2024-05-07 |
2025-11-13 |
Innate Pharma |
Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
|
|
WO2025233266A1
(en)
|
2024-05-07 |
2025-11-13 |
Innate Pharma |
Use of cd39 blocking agents in combination with anti-cd20 x cd3 t cell engagers
|
|
WO2026006162A2
(en)
|
2024-06-24 |
2026-01-02 |
Genentech, Inc. |
B vitamin modulation
|
|
WO2026030473A1
(en)
|
2024-07-31 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
West nile virus neutralizing monoclonal antibodies
|
|
WO2026032438A1
(zh)
*
|
2024-08-08 |
2026-02-12 |
惠和生物技术(上海)有限公司 |
多特异性抗体治疗自身免疫性疾病的用途
|
|
WO2026041568A1
(en)
|
2024-08-20 |
2026-02-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and dotam
|